Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Authors' conclusion
In this analysis of AUGUSTUS, there was no difference in DAOH by treatment arm.
Study context
- Population
- Patients with AF and ACS or PCI
- Participants
- 4,614 patients
- Comparison
- Apixaban vs warfarin and aspirin vs placebo
- Primary endpoint
- Days alive and out of hospital (DAOH)
Methodological detailsfactorial
- Factorial
Primary result
As reported in the abstract
DAOH
Relative risk (95% CI)
Apixabanvs Warfarin
1.00(0.99–1.01)
Aspirinvs Placebo
1.00(1.00–1.01)
Further findings
| Outcome | Apixaban | Warfarin | OR (95% CI) | |
|---|---|---|---|---|
| Neither died nor hospitalized during follow-up | 76.8 % | 73.3% | 0.83 (0.73–0.95) | |
| 0.512Odds ratio (log scale) |
- Neither died nor hospitalized during follow-up: 75% of all patients neither died nor were hospitalized
Original publication
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. Am Heart J. Published 17 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →